½ÃÀ庸°í¼­
»óǰÄÚµå
1538606

¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå ±Ô¸ð Á¶»ç : Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)

Global Blood Transfusion Diagnostics Market Size Study, by Product Type, by Application, by End-user, and Regional Forecasts 2022-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 285 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀåÀº 2023³â¿¡ ¾à 46¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2024-2032³â¿¡´Â 4.9% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼öÇ÷ Áø´ÜÀº ¼öÇ÷ Àü¿¡ ȯÀÚ¿Í ÇåÇ÷ÀÚ¸¦ ¸ðµÎ °Ë»çÇÏ¿© ÀûÇÕ¼ºÀ» È®ÀÎÇÏ´Â Áß¿äÇÑ °úÁ¤ÀÔ´Ï´Ù. ÀÌ °úÁ¤¿¡´Â Ç÷¾×Çü(ABO ¹× Rh) °áÁ¤, ȯÀÚÀÇ Ç÷¾×³» Ç×ü È®ÀÎ, ºÎÀÛ¿ëÀ» ¿¹¹æÇϰí Ç÷¾× Á¦Á¦ÀÇ ¾ÈÀüÇϰí È¿°úÀûÀÎ Åõ¿©¸¦ º¸ÀåÇϱâ À§ÇÑ °¨¿° ¿©ºÎ È®ÀÎ µîÀÌ Æ÷ÇԵ˴ϴÙ.

Àü ¼¼°è¿¡¼­ Ç÷¾× ÁúȯÀÇ À¯º´·ü Áõ°¡, ±³Åë»ç°í¿Í ¼ö¼ú Áõ°¡, Àü ¼¼°è ³ëÀÎ Àα¸ÀÇ ±Þ°ÝÇÑ Áõ°¡´Â ¾ÈÀüÇÑ ¼öÇ÷¿ë Ç÷¾×¿¡ ´ëÇÑ ¼ö¿ä¸¦ Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼öÇ÷ Áø´ÜÀº ±âÁõÀÚ¿Í ¼öÇýÀÚÀÇ ÀûÇÕ¼ºÀ» º¸ÀåÇϰí Ç÷¾×¿¡ Á¸ÀçÇÒ ¼ö ÀÖ´Â °¨¿°¼º ÁúȯÀ» ¼±º°ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¹éÇ÷º´, ÁöÁßÇØºóÇ÷, °â»ó ÀûÇ÷±¸ ºóÇ÷, Ç÷¿ìº´°ú °°Àº Ç÷¾× Áúȯ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹éÇ÷º´ ¸²ÇÁÁ¾ Çùȸ¿¡ µû¸£¸é 2023³â ¹Ì±¹¿¡¼­ 59,610¸íÀÇ ¹éÇ÷º´ ȯÀÚ°¡ »õ·Î Áø´Ü¹Þ°í 23,710¸íÀÌ ¹éÇ÷º´À¸·Î »ç¸ÁÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)´Â Àü ¼¼°è Àα¸ÀÇ 5%°¡ Çì¸ð±Û·Îºó Àå¾Ö, ƯÈ÷ ÁöÁßÇØºóÇ÷°ú °â»ó ÀûÇ÷±¸ ºóÇ÷ÀÇ ÇüÁú À¯ÀüÀÚ º¸À¯ÀÚÀ̸ç, ¸Å³â 30¸¸ ¸í ÀÌ»óÀÇ À¯¾Æ°¡ ½É°¢ÇÑ Çì¸ð±Û·Îºó Àå¾Ö¸¦ °¡Áö°í ž´Â °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù.

±×·¯³ª ÀÚµ¿ ÁÖÀÔ ½Ã½ºÅÛ¿¡ ³»ÀçµÈ ¹®Á¦Á¡°ú ÀûÇÕ¼º Å×½ºÆ®ÀÇ º¹À⼺Àº ¼¼°è ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ÀúÇØÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇåÇ÷ °ü¸® ½Ã½ºÅÛÀÇ ±â¼ú Çõ½Å Áõ°¡´Â ¾÷°è¿¡ Å« º¯È­¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ÀÚµ¿È­ ½Ã½ºÅÛÀº ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÏ°í º¸´Ù È¿À²ÀûÀÌ°í ½Ç¼ö ¾øÀÌ ÀÛ¾÷ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ±â¾÷Àº ÃÖ÷´Ü ¼ÒÇÁÆ®¿þ¾î¿Í ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ÇÀ» µµÀÔÇÏ¿© ÇåÇ÷ÀÚ Âü¿©¸¦ °­È­Çϰí, ¾à¼ÓÀ» ¿¹¾àÇϰí, ¾Ë¸²À» º¸³»°í, ÇåÇ÷ ÈÄ °ü¸® ÁöħÀ» Á¦°øÇÏ´Â µî ÇåÇ÷ÀÚÀÇ Âü¿©¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. ÷´Ü °ü¸® ½Ã½ºÅÛ°ú Ŭ¶ó¿ìµå ±â¹Ý ±â¼úÀ» ÅëÇØ ±âÁõÀÚ Á¤º¸¸¦ ¾ÈÀüÇÏ°Ô ÀúÀåÇÏ°í ½±°Ô °Ë»öÇÒ ¼ö ÀÖÀ¸¸ç, ±âÁõÀÚ¿¡¼­ ¼öÇýÀÚ±îÁö ÃßÀûÇÒ ¼ö ÀÖÀ¸¸ç, ¼öÇ÷ Áø´Ü ½ÃÀå¿¡ À¯¸®ÇÑ ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

¼öÇ÷ Áø´Ü ½ÃÀåÀ» Á¦Ç° À¯Çüº°·Î ºÐ·ùÇÏ¸é ±â±â, ŰƮ ¹× ½Ã¾àÀÌ Æ÷ÇԵ˴ϴÙ. ŰƮ ¹× ½Ã¾àÀº ABO Ç÷¾×Çü °Ë»ç, Rh Ç÷¾×Çü °Ë»ç, È®Àå Ç¥ÇöÇü °Ë»ç, RBC Ç×ü °Ë»ç, Ç÷ûÇÐÀû ¹× ºÐÀÚ»ý¹°ÇÐÀû Áúº´ °Ë»ç µî ´Ù¾çÇÑ ¼öÇ÷ Àü °Ë»ç¸¦ ¼öÇàÇÏ´Â µ¥ ÇʼöÀûÀ̸ç, ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ Áö¿ªÀÔ´Ï´Ù. ºÏ¹Ì´Â ÀÇ·á ÀÎÇÁ¶óÀÇ ¹ßÀü, ÀÎÁöµµ Çâ»ó, ÀÇ·á ÀçÁ¤ °­È­·Î ÀÎÇØ 2023³â ¾ÐµµÀûÀÎ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹¿¡¼­´Â °í·ÉÈ­ »çȸ°¡ ÁøÇàµÊ¿¡ µû¶ó ÀçÅÃÄ¡·á ºÐ¾ß¿¡¼­ ÀÚµ¿ Á¤Á¦ Æ÷Àå ±â°è¿¡ ´ëÇÑ ¼ö¿ä°¡ ¸¹À¸¸ç, 2024³â 3¿ù ·Î½´´Â ÄÚ¹Ù½º 6800/8800 ½Ã½ºÅÛ¿¡ »ç¿ëµÇ´Â ÄÚ¹Ù½º ¸»¶ó¸®¾Æ °Ë»ç¿¡ ´ëÇÑ ¹Ì±¹ FDAÀÇ ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ÀϺ», Àεµ, Áß±¹ µîÀÇ ±¹°¡¿¡¼­ ÁÖ¿ä Ç÷¾× °ü·Ã ÁúȯÀÌ ±ÞÁõÇϰí ÀÖÀ¸¸ç, Áø´Ü¿ë ÀÚµ¿ ÀåºñÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ°í ´Ù±¹Àû ±â¾÷ ½ÃÀå ÁøÀÔÀÌ °¡Àå ³ôÀº CAGR·Î ½ÃÀåÀ» È®´ëÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå °³¿ä

  • ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå ±Ô¸ð¡¤¿¹Ãø(2022-2032³â)
  • Áö¿ªº° °³¿ä
  • ºÎ¹®º° °³¿ä
  • ÁÖ¿ä µ¿Çâ
  • °æ±âÈÄÅðÀÇ ¿µÇâ
  • ¾Ö³Î¸®½ºÆ® °á·Ð¡¤Á¦¾È

Á¦2Àå ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå Á¤ÀÇ¿Í Á¶»ç ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ÀüÁ¦Á¶°Ç
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ »çÇ×
    • °ø±ÞÃø ºÐ¼®
      • °¡¿ë¼º
      • ÀÎÇÁ¶ó
      • ±ÔÁ¦ ȯ°æ
      • ½ÃÀå °æÀï
      • °æÁ¦¼º(¼ÒºñÀÚÀÇ ½ÃÁ¡)
    • ¼ö¿äÃø ºÐ¼®
      • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
      • ±â¼úÀÇ Áøº¸
      • ģȯ°æ
      • ¼ÒºñÀÚÀÇ Àǽİú ¼ö¿ë
  • Á¶»ç ¹æ¹ý
  • Á¶»ç ´ë»ó³â
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Ç÷¾× ÁúȯÀÇ ¼¼°è À¯º´·üÀÇ »ó½Â
    • ±³Åë»ç°í ¹× ¼ö¼ú °Ç¼öÀÇ Áõ°¡
    • ¼¼°è ³ëÀÎ Àα¸ÀÇ ±ÞÁõ
  • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • ÀÚµ¿ ºÐÁÖ ½Ã½ºÅÛ¿¡ ³»ÀçÇÏ´Â °úÁ¦
    • ÀûÇÕ ½ÃÇèÀÇ º¹À⼺
  • ½ÃÀå ±âȸ
    • ¼öÇ÷ Áø´ÜÀÇ ±â¼úÀû Áøº¸
    • °øµ¿ ¿¬±¸ ¹× ÆÄÆ®³Ê½ÊÀÇ Áõ°¡
    • ÀÚµ¿È­ ½Ã½ºÅÛÀÇ Ã¤Åà Áõ°¡

Á¦4Àå ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷ °£ °æÀï °ü°è
    • Porter's Five Forces ¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû ¾îÇÁ·ÎÄ¡
    • Porter's Five ForcesÀÇ ¿µÇ⠺м®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ® °á·Ð¡¤Á¦¾È

Á¦5Àå ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Ç° À¯Çüº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • ±â±â
    • ŰƮ ¹× ½Ã¾à

Á¦6Àå ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • Ç÷¾×Çü ºÐ·ù
    • Áúȯ ½ºÅ©¸®´×

Á¦7Àå ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • Ç÷¾×ÀºÇà
    • ÇåÇ÷/¼öÇ÷ ¼¾ÅÍ
    • ±âŸ

Á¦8Àå ¼¼°èÀÇ ¼öÇ÷ Áø´Ü ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Grifols, S.A.
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍÀÇ °¡¿ë¼º¿¡ µû¸§)
      • Á¦Ç° °³¿ä
      • ½ÃÀå Àü·«
    • F. Hoffmann-La Roche Ltd.
    • Abbott
    • Bio-Rad Laboratories, Inc.
    • Werfen, S.A.
    • QuidelOrtho Corporation
    • AliveDx Holdings Finance Company Ltd
    • BAG Diagnostics GmbH
    • Diasorin S.p.A.
    • Prestige Diagnostics U.K. Ltd.
    • Atlas Medical GmbH
    • Lorne Laboratories Limited
    • Ortho Clinical Diagnostics
    • Quotient Limited
    • Beckman Coulter Inc.

Á¦10Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
KSA 24.09.10

Global Blood Transfusion Diagnostics Market is valued at approximately USD 4.6 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.9% over the forecast period 2024-2032. Blood transfusion diagnostics are a critical process involving the testing of both the patient and the blood donor to ensure compatibility before a transfusion. This process includes determining blood types (ABO and Rh), identifying antibodies in the patient's blood, and checking for infectious diseases to prevent adverse reactions and ensure the safe and effective administration of blood products.

The increasing global prevalence of blood disorders, a rise in road accidents and surgeries, and the surge in the global geriatric population are significantly driving the demand for safe transfusion blood. Blood transfusion diagnostics play a crucial role in ensuring donor-recipient compatibility and screening for infections that might be present in blood. The rise in blood disorders like leukemia, thalassemia, sickle cell anemia, and hemophilia is further propelling the market growth. In 2023, an estimated 59,610 new leukemia cases were diagnosed in the U.S., with 23,710 deaths attributed to leukemia, according to the Leukemia and Lymphoma Society. The World Health Organization (WHO) estimates that 5% of the global population are carriers of trait genes for hemoglobin disorders, specifically thalassemia and sickle cell anemia, with over 300,000 infants born with severe hemoglobin disorders annually.

However, inherent challenges with automation dispensing systems and complexities in compatibility testing are the key factors that are substantially halting the growth of the market globally. Moreover, the rising technological innovations in blood donor management systems have brought significant changes to the industry. Automated systems have streamlined workflows, making them more efficient and error-free. Companies have introduced cutting-edge software and mobile applications to enhance donor engagement, scheduling appointments, sending reminders, and offering post-donation care instructions. Advanced management systems and cloud-based technologies have enabled secure storage and easy retrieval of donor information, improving traceability from donor to recipient, and thus offering lucrative opportunities in the blood transfusion diagnostics market.

The blood transfusion diagnostics market segmentation based on product type includes instruments and kits and reagents. Kits and reagents are essential for conducting various pre-transfusion tests such as ABO blood typing, Rh typing, extended phenotyping, RBC antibody screening, and serological and molecular disease screening, driving the growth of this segment.

The key regions considered for the global blood transfusion diagnostics market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America held a dominant market share in 2023 due to advancements in healthcare infrastructure, increased awareness, and augmented healthcare finances. The U.S. sees significant demand for automated pill dispensers from the home healthcare segment, driven by a growing aging population. In March 2024, Roche received U.S. FDA approval for its cobas Malaria test for use on the cobas 6800/8800 Systems, aimed at reducing the potential risk of malarial infection from transfused blood products. In Asia Pacific, the expansion of the market at the highest CAGR is ascribed to the steep increase in major blood-related disorders in countries such as Japan, India, and China, coupled with the rise in adoption of automated instruments for diagnostics and entry of multinational firms within the marketplace.

Major market players included in this report are:

  • Grifols, S.A.
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Bio-Rad Laboratories, Inc.
  • Werfen, S.A.
  • QuidelOrtho Corporation
  • AliveDx Holdings Finance Company Ltd
  • BAG Diagnostics GmbH
  • Diasorin S.p.A.
  • Prestige Diagnostics U.K. Ltd.
  • Atlas Medical GmbH
  • Lorne Laboratories Limited
  • Ortho Clinical Diagnostics
  • Quotient Limited
  • Beckman Coulter Inc.

The detailed segments and sub-segment of the market are explained below:

By Product Type:

  • Instruments
  • Kits and Reagents

By Application:

  • Blood Grouping
  • Disease Screening

By End-user:

  • Blood Banks
  • Blood Donation/Transfusion Centers
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Blood Transfusion Diagnostics Market Executive Summary

  • 1.1. Global Blood Transfusion Diagnostics Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Product Type
    • 1.3.2. By Application
    • 1.3.3. By End-user
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Blood Transfusion Diagnostics Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Blood Transfusion Diagnostics Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Rise in global prevalence of blood disorders
    • 3.1.2. Increase in number of road accidents and surgeries
    • 3.1.3. Surge in global geriatric population
  • 3.2. Market Challenges
    • 3.2.1. Inherent challenges with automation dispensing systems
    • 3.2.2. Complexities in compatibility testing
  • 3.3. Market Opportunities
    • 3.3.1. Technological advancements in blood transfusion diagnostics
    • 3.3.2. Increasing collaborations and partnerships
    • 3.3.3. Rise in adoption of automated systems

Chapter 4. Global Blood Transfusion Diagnostics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top investment opportunity
  • 4.4. Top winning strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Blood Transfusion Diagnostics Market Size & Forecasts by Product Type 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Blood Transfusion Diagnostics Market: Product Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 5.2.1. Instruments
    • 5.2.2. Kits and Reagents

Chapter 6. Global Blood Transfusion Diagnostics Market Size & Forecasts by Application 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Blood Transfusion Diagnostics Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 6.2.1. Blood Grouping
    • 6.2.2. Disease Screening

Chapter 7. Global Blood Transfusion Diagnostics Market Size & Forecasts by End-user 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Global Blood Transfusion Diagnostics Market: End-user Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 7.2.1. Blood Banks
    • 7.2.2. Blood Donation/Transfusion Centers
    • 7.2.3. Others

Chapter 8. Global Blood Transfusion Diagnostics Market Size & Forecasts by Region 2022-2032

  • 8.1. North America Blood Transfusion Diagnostics Market
    • 8.1.1. U.S. Blood Transfusion Diagnostics Market
      • 8.1.1.1. Product Type breakdown size & forecasts, 2022-2032
      • 8.1.1.2. Application breakdown size & forecasts, 2022-2032
      • 8.1.1.3. End-user breakdown size & forecasts, 2022-2032
    • 8.1.2. Canada Blood Transfusion Diagnostics Market
  • 8.2. Europe Blood Transfusion Diagnostics Market
    • 8.2.1. U.K. Blood Transfusion Diagnostics Market
    • 8.2.2. Germany Blood Transfusion Diagnostics Market
    • 8.2.3. France Blood Transfusion Diagnostics Market
    • 8.2.4. Spain Blood Transfusion Diagnostics Market
    • 8.2.5. Italy Blood Transfusion Diagnostics Market
    • 8.2.6. Rest of Europe Blood Transfusion Diagnostics Market
  • 8.3. Asia-Pacific Blood Transfusion Diagnostics Market
    • 8.3.1. China Blood Transfusion Diagnostics Market
    • 8.3.2. India Blood Transfusion Diagnostics Market
    • 8.3.3. Japan Blood Transfusion Diagnostics Market
    • 8.3.4. Australia Blood Transfusion Diagnostics Market
    • 8.3.5. South Korea Blood Transfusion Diagnostics Market
    • 8.3.6. Rest of Asia Pacific Blood Transfusion Diagnostics Market
  • 8.4. Latin America Blood Transfusion Diagnostics Market
    • 8.4.1. Brazil Blood Transfusion Diagnostics Market
    • 8.4.2. Mexico Blood Transfusion Diagnostics Market
    • 8.4.3. Rest of Latin America Blood Transfusion Diagnostics Market
  • 8.5. Middle East & Africa Blood Transfusion Diagnostics Market
    • 8.5.1. Saudi Arabia Blood Transfusion Diagnostics Market
    • 8.5.2. South Africa Blood Transfusion Diagnostics Market
    • 8.5.3. Rest of Middle East & Africa Blood Transfusion Diagnostics Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Grifols, S.A.
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Market Strategies
    • 9.3.2. F. Hoffmann-La Roche Ltd.
    • 9.3.3. Abbott
    • 9.3.4. Bio-Rad Laboratories, Inc.
    • 9.3.5. Werfen, S.A.
    • 9.3.6. QuidelOrtho Corporation
    • 9.3.7. AliveDx Holdings Finance Company Ltd
    • 9.3.8. BAG Diagnostics GmbH
    • 9.3.9. Diasorin S.p.A.
    • 9.3.10. Prestige Diagnostics U.K. Ltd.
    • 9.3.11. Atlas Medical GmbH
    • 9.3.12. Lorne Laboratories Limited
    • 9.3.13. Ortho Clinical Diagnostics
    • 9.3.14. Quotient Limited
    • 9.3.15. Beckman Coulter Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦